We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TMS DEVICE EFFECTIVE IN TREATING MIGRAINES

TMS DEVICE EFFECTIVE IN TREATING MIGRAINES

June 29, 2006

An experimental device appears to be effective in eliminating or reducing migraine headaches when administered during the onset of the migraine, according to a study conducted at the Ohio State University (OSU) Medical Center.

The device, called transcutaneous magnetic stimulation (TMS), interrupts the "aura phase" of the migraine, often described as "electrical storms" in the brain. Auras are neural disturbances that signal the onset of migraine headaches.

The stimulator sends an electric current through a metal coil, which creates an intense magnetic field. When held against a person's head, this magnetic pulse creates an electric current in the neurons of the brain, interrupting the aura before it results in a throbbing headache.

Patients in the Phase II study reported a significant reduction in nausea, noise and light sensitivity after TMS treatment, said Yousef Mohammad, principal investigator and a neurologist at the OSU Medical Center.

"Perhaps the most significant effect of using the TMS device was on the two-hour symptom assessment, with 84 percent of the episodes in patients using the TMS occurring without noise sensitivity. Work functioning also improved and there were no side effects reported," Mohammad said, adding that the device's pulses are painless and patients reported feeling a "little pressure, but that's all." So far, the device has been tested on 70 people at OSU, he added.

In the study sample, 69 percent of the TMS-treated patients reported mild or no pain at the two-hour post-treatment point compared with 48 percent of the placebo group, Mohammad said.

In addition, 42 percent of the TMS-treated patients graded their headache response "as very good or excellent compared to 26 percent for the placebo group."

(http://www.fdanews.com/ddl/33_26/)

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing